Safety and Immunogenicity of Inactivated COVID-19 Vaccines Among People Living with HIV in China

References

• World Health Organization. WHO coronavirus (COVID-19) dashboard. Available from: https://covid19.who.int/. Accessed March 12, 2022.
   Google Scholar
• Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet. 2021;397(10277):875–877. doi:10.1016/s0140-6736(21)00448-7
   PubMed Web of Science ®Google Scholar
• Frater J, Ewer KJ, Ogbe A, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a Phase 2/3 clinical trial. Lancet HIV. 2021;8(8):e474–e485. doi:10.1016/s2352-3018(21)00103-x
   PubMed Web of Science ®Google Scholar
• Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(6):803–812. doi:10.1016/s1473-3099(20)30987-7
   PubMed Web of Science ®Google Scholar
• Yang S, Li Y, Dai L, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021;21(8):1107–1119. doi:10.1016/s1473-3099(21)00127-4
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181–192. doi:10.1016/s1473-3099(20)30843-4
   PubMed Web of Science ®Google Scholar
• Yang X, Sun J, Patel R, et al. Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data. Lancet HIV. 2021;8(11):e690–e700. doi:10.1016/s2352-3018(21)00239-3
   Web of Science ®Google Scholar
• Hiv T. Prioritise people with HIV for COVID-19 vaccination. Lancet HIV. 2021;8(11):e659. doi:10.1016/s2352-3018(21)00278-2
   Web of Science ®Google Scholar
• Koutsakos M, Lee WS, Wheatley AK, Kent SJ, Juno JA. T follicular helper cells in the humoral immune response to SARS-CoV-2 infection and vaccination. J Leukoc Biol. 2022;111(2):355–365. doi:10.1002/jlb.5mr0821-464r
   Web of Science ®Google Scholar
• Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861–880. doi:10.1016/j.cell.2021.01.007
   PubMed Web of Science ®Google Scholar
• Crotty S. T follicular helper cell biology: a decade of discovery and diseases. Immunity. 2019;50(5):1132–1148. doi:10.1016/j.immuni.2019.04.011
   PubMed Web of Science ®Google Scholar
• Levy I, Wieder-Finesod A, Litchevsky V, et al. Immunogenicity and safety of the BNT162b2 mRNA Covid-19 vaccine in people living with HIV-1. Clin Microbiol Infect. 2021;27(12):1851–1855. doi:10.1016/j.cmi.2021.07.031
   PubMed Web of Science ®Google Scholar
• Davies N, Jarvis C, Edmunds W, Jewell N, Diaz-Ordaz K, Keogh R. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021;593(7858):270–274. doi:10.1038/s41586-021-03426-1
   PubMed Web of Science ®Google Scholar
• Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397(10293):2461–2462. doi:10.1016/s0140-6736(21)01358-1
   PubMed Web of Science ®Google Scholar
• Nie J, Li Q, Wu J, et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect. 2020;9(1):680–686. doi:10.1080/22221751.2020.1743767
   PubMed Web of Science ®Google Scholar
• Nie J, Li Q, Wu J, et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat Protoc. 2020;15(11):3699–3715. doi:10.1038/s41596-020-0394-5
   PubMed Web of Science ®Google Scholar
• Handoko R, Colby D, Kroon E, et al. Determinants of suboptimal CD4 T cell recovery after antiretroviral therapy initiation in a prospective cohort of acute HIV-1 infection. J Int AIDS Soc. 2020;23(9):e25585. doi:10.1002/jia2.25585
   Web of Science ®Google Scholar
• Ibarz-Pavon A, French N. No changes on viral load and CD4+ T-cell counts following immunization with 7-valent pneumococcal conjugate vaccine among HIV-infected adults in Malawi. Vaccine. 2018;36(19):2504–2506. doi:10.1016/j.vaccine.2018.04.009
   Web of Science ®Google Scholar
• El Chaer F, El Sahly H. Vaccination in the adult patient infected with HIV: a review of vaccine efficacy and immunogenicity. Am J Med. 2019;132(4):437–446. doi:10.1016/j.amjmed.201
   Web of Science ®Google Scholar
• Tebas P, Frank I, Lewis M, et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS. 2010;24(14):2187–2192. doi:10.1097/QAD.0b013e32833
   Web of Science ®Google Scholar
• Balcells ME, Le Corre N, Durán J, et al. Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile. Clin Infect Dis. 2022. doi:10.1093/cid/ciac167
   Web of Science ®Google Scholar
• Liu Y, Han J, Li X, et al. COVID-19 vaccination in people living with HIV (PLWH) in China: a cross sectional study of vaccine hesitancy, safety, and immunogenicity. Vaccines. 2021;9(12):1458. doi:10.3390/vaccines9121458
   Web of Science ®Google Scholar
• Lv Z, Li Q, Feng Z, et al. Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV. Int Immunopharmacol. 2021;102:108383. doi:10.1016/j.intimp.2021108383
   Web of Science ®Google Scholar
• Jalkanen P, Kolehmainen P, Häkkinen H, et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat Commun. 2021;12(1):3991. doi:10.1038/s41467-021-24285-4
   PubMed Web of Science ®Google Scholar
• Liu C, Ginn H, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021;184(16):4220–4236.e13. doi:10.1016/j.cell.2021.06.020
   PubMed Web of Science ®Google Scholar
• Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385(16):1474–1484. doi:10.1056/NEJMoa2109072
   PubMed Web of Science ®Google Scholar
• Li XN, Huang Y, Wang W, et al. Effectiveness of inactivated SARS-CoV-2 vaccines against the delta variant infection in Guangzhou: a test-negative case-control real-world study. Emerg Microbes Infect. 2021;10(1):1751–1759. doi:10.1080/22221751.2021.1969291
   PubMed Web of Science ®Google Scholar
• Melo-González F, Soto J, González L, et al. Recognition of variants of concern by antibodies and t cells induced by a SARS-CoV-2 inactivated vaccine. Front Immunol. 2021;12:747830. doi:10.3389/fimmu.2021.747830
   Web of Science ®Google Scholar
• Khandelwal N, Chander Y, Kumar R, et al. Studies on growth characteristics and cross-neutralization of wild-type and delta SARS-CoV-2 from Hisar (India). Front Cell Infect Microbiol. 2021;11:771524. doi:10.3389/fcimb.2021.771524
   Web of Science ®Google Scholar
• Xiang Q, Li L, Wu J, Tian M, Fu Y. Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies. Microbiol Res. 2022;258:126993. doi:10.1016/j.micres.2022.126993
   PubMed Web of Science ®Google Scholar
• Li Q, Liu Q, Huang W, Li X, Wang Y. Current status on the development of pseudoviruses for enveloped viruses. Rev Med Virol. 2018;28(1):e1963. doi:10.1002/rmv.1963
   PubMed Web of Science ®Google Scholar